StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals stock opened at $3.57 on Wednesday. The company’s 50 day simple moving average is $3.46 and its 200 day simple moving average is $4.58. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- 3 Must-Have ETFs Set to Dominate This Quarter
- What Makes a Stock a Good Dividend Stock?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Investing in the High PE Growth Stocks
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
